You are here

Amgen

Coherus' Neulasta biosimilar surprises with strong early uptake

Biopharma Dive

Mon, 04/8/19 - 05:44 pm

Coherus Biosciences

Lawsuit over migraine deal could be good for Amgen, analysts say

Marketwatch

Sat, 04/6/19 - 02:09 pm

Amgen and Novartis file dueling lawsuits over their deal to market a migraine drug

Stat

Thu, 04/4/19 - 11:22 pm

Novartis sues Amgen over migraine treatment Aimovig

Yahoo/Reuters

Thu, 04/4/19 - 12:04 pm

Sandoz resubmission puts Amgen's Neulasta at further risk of competition

Biopharma Dive

Wed, 04/3/19 - 09:31 pm

3 Leading Alzheimer's Disease Drugs in Development After Biogen's Aducanumab Flop

Motley Fool

Sat, 03/30/19 - 12:44 pm

Alzheimer's disease

Axsome Therapeutics

Amgen, Servier heart failure drug clears trial hurdle

PM Live

Thu, 03/21/19 - 06:50 pm

Omecamtiv Mecarbil

clinical trials

Can Amgen Leapfrog A Key Rival And Add Millions Of New Patients?

Investors Business Daily

Sat, 03/16/19 - 12:21 pm

clinical trials

Amgen's top-selling Enbrel in balance as key court ruling nears

Biopharma Dive

Wed, 03/13/19 - 04:32 pm

3 Big Pharmas Trying to Pop the Rebate Bubble

Motley Fool

Wed, 03/6/19 - 10:06 am

Gilead Sciences

Top 10 drugs losing exclusivity in 2019

Fierce Pharma

Tue, 03/5/19 - 09:40 am

market exclusivity

Gilead Sciences

A Closer Look At The Drug Rebate Proposal

Forbes

Sat, 03/2/19 - 12:57 pm

healthcare reform

Amgen and partners begin second phase 3 trial of omecamtiv mecarbil in patients with heart failure

Pharmaceutical Business Review

Fri, 02/22/19 - 10:04 am

heart failure with reduced ejection fraction

Omecamtiv Mecarbil

Regeneron, Sanofi cut PCSK9 list price, matching earlier move by rival Amgen

Biopharma Dive

Mon, 02/11/19 - 12:23 pm

PCSK9 inhibitors

Q4 Biopharma Themes: Strong 2018, Weaker 2019 Earnings Projections, Concerns over Drug Pricing

BioSpace

Fri, 02/1/19 - 11:27 am

Report: five companies would take brunt of Trump Part B proposal

BioCentury

Fri, 02/1/19 - 11:24 am

Medicare Part B

Bristol-Myers Squibb

Even with new competition, Botox can hold its own in growing migraine field: Allergan executives

Fierce Pharma

Thu, 01/31/19 - 11:49 am

Teva Pharmaceuticals

Calico brings on Amgen’s translational R&D head to lead early drug development

Fierce Biotech

Thu, 01/31/19 - 11:26 am

Calico Life Sciences

Amgen hunts for deals of all sizes to combat forthcoming sales decline

Fierce Pharma

Tue, 01/29/19 - 11:17 pm

CVS to cover migraine drugs from Teva, Lilly; excludes Amgen

Reuters

Sat, 01/26/19 - 11:56 am

Teva Pharmaceutical

Pages